A year has 8,760 hours. Support the campaign
Vitruvian Shield
CROs

Built for contract research organisations

Hybrid trial components for the studies you run for sponsors, under your own contracts: CTMS, EDC, eConsent, ePRO and remote patient monitoring on one platform, used individually or together.

The challenges you face

Sponsor technology requirements

Every sponsor has different technology preferences. Supporting multiple platforms across your portfolio drains resources and creates training overhead.

Operational scalability

Growing your trial volume without proportionally increasing headcount requires standardised, automated workflows that current tools don't provide.

Differentiation pressure

Sponsors ask for hybrid components and fewer separate systems. Building those tools in-house takes an investment most CROs cannot justify.

Multi-sponsor compliance

Managing compliance requirements across dozens of simultaneous studies for different sponsors creates audit risk and operational complexity.

Data delivery timelines

Sponsors expect faster database locks, cleaner data, and real-time visibility into trial progress. Legacy tools create bottlenecks at every stage.

How Vitruvian Shield helps

Under your contracts, beside the sponsor's EDC

The platform is contracted by the CRO for the studies it runs and delivers data into the EDC the sponsor already uses, so the sponsor's systems do not change. Co-branded deployments are available on request.

Standardised workflows

Template-driven study setup, reusable eCRF libraries, and automated workflows let you launch studies faster and execute them more consistently.

Multi-study dashboard

Manage your entire portfolio from a single operational dashboard. Cross-study analytics, resource allocation views, and KPI tracking across all active trials.

One dataset from home

eConsent, patient-reported outcomes on the participant's own phone, and wearable and device data arrive in one dataset, each record with provenance and an audit trail.

Faster data delivery

Real-time validation, coding support and CDISC-aligned exports shorten the path from last patient out to database lock.

Why it matters from 15 January 2027

ICH E6(R3) Annex 2, which applies in the EU from 15 January 2027, sets out what sponsors must be able to show for remote consent, data from digital health technologies and investigator oversight of activities outside the site. The platform is designed to support sponsors and CROs in meeting these expectations.

Book a demonstration

ICH E6(R3) readiness

The ICH E6(R3) principles and Annex 1 have applied in the EU since 23 July 2025. Annex 2, on decentralised and pragmatic trial elements, applies from 15 January 2027.

The platform is designed to support sponsors and CROs in meeting these expectations: remote consent, data from digital health technologies and investigator oversight of activities outside the site. This is a design statement, not a certification.

CRO partnership

Small and mid-size CROs can offer the platform to their sponsors under partner terms. The CRO keeps the sponsor relationship and runs the study; Vitruvian Shield supplies and supports the platform.

Sponsor validation and vendor-qualification pack

The documentation sponsors and CROs need to qualify the platform as a vendor.

Delivery schedule agreed in the written proposal.

See it in action

What Vitruvian Shield Offers CROs and Hospitals

A quick tour of the platform value for mid-market CROs and hospital research units.